Navigation Links
Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension
Date:7/12/2011

SAN DIEGO, July 12, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today results from a Phase 1 clinical trial of APD811, an orally bioavailable agonist of the prostacyclin receptor which is intended for the treatment of pulmonary arterial hypertension, or PAH.

The randomized, double-blind and placebo-controlled trial evaluated the safety, tolerability and pharmacokinetics of 0.03 mg, 0.05 mg, 0.1 mg and 0.2 mg single doses of APD811. The trial evaluated 32 healthy volunteers in four cohorts of eight participants each – six randomized to APD811 and two to placebo. APD811 was rapidly absorbed and demonstrated dose-proportional pharmacokinetic exposure over the tested dose range. The terminal half-life was approximately 20 hours.

The most frequent treatment-emergent adverse events were headache, vomiting, nausea, jaw pain and flushing. Dose-limiting adverse events of nausea and vomiting occurred at the 0.2 mg dose. As compared to placebo, heart rate trended higher at the 0.05 mg, 0.1 mg and 0.2 mg doses and the corrected QT (QTc) interval trended higher at the 0.1 mg and 0.2 mg doses. Arena believes the QTc observation is not supported by preclinical data and will further evaluate this in future studies. No serious adverse events were reported.

"We are encouraged by the results of this early stage clinical trial that suggest APD811 has the potential for once-daily, oral dosing, and our next step will be to evaluate the safety, tolerability and pharmacokinetics of multiple dosing and the optimal titration schedule in a Phase 1b trial," said William R. Shanahan, M.D., Arena's Senior Vice President and Chief Medical Officer. "The development of APD811 is the result of Arena's continuing commitment to advance our diverse research and development pipeline."

About Pulmonary Arterial Hypertension (PAH)PAH is a progressi
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals Lorcaserin Achieved Statistically Significant Weight Loss
2. Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments
3. Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
4. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10
5. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Financial Results and Reviews Recent Developments
6. Arena Pharmaceuticals Expands GPR119 Patent Portfolio for Type 2 Diabetes
7. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Friday, March 11
8. Arena Pharmaceuticals Announces Upcoming Departure of Chief Financial Officer
9. Arena Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
10. Arena and Eisai Complete End-of-Review Meeting with FDA for Lorcaserin New Drug Application
11. Arena Pharmaceuticals to Host Conference Call and Webcast to Provide Update Following Lorcaserin End-of-Review Meeting With FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... DIEGO and PARIS , ... VOLC ), a leading developer and manufacturer of precision ... treatment of coronary and peripheral vascular disease, today announced ... V asodilator I ndependent S tenosis ... breaking clinical trial session at EuroPCR 2013. These prospective ...
(Date:5/23/2013)... -- Nederland keurt als eerste nieuwe vaste-dosis ... BPH Astellas Pharma EUROPE ... gebaseerd in Tokyo  ( ... Nederlandse College ter Beoordeling van Geneesmiddelen (CBG) een handelsvergunning ... handelsvergunning verleend voor VESOMNI is voor "de behandeling van ...
(Date:5/23/2013)... , Switzerland and ... 2013 Cenix BioScience, a ... specialized in RNAi-, miRNA- and high content-driven pharmacology, ... group of companies with a focus on the ... needs, including oncology and companion diagnostics, today announced ...
Breaking Medicine Technology:Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 2Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 3Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 4Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 5Astellas ontvangt handelsvergunning voor VESOMNITM van Nederlandse College ter Beoordeling van Geneesmiddelen 2Astellas ontvangt handelsvergunning voor VESOMNITM van Nederlandse College ter Beoordeling van Geneesmiddelen 3Astellas ontvangt handelsvergunning voor VESOMNITM van Nederlandse College ter Beoordeling van Geneesmiddelen 4Cenix BioScience and Debiopharm Group Collaborate to Identify Predictive Biomarkers 2Cenix BioScience and Debiopharm Group Collaborate to Identify Predictive Biomarkers 3Cenix BioScience and Debiopharm Group Collaborate to Identify Predictive Biomarkers 4
... PARSIPPANY, N.J. , June 28 Preliminary ... with diabetes and hypertension demonstrated that the investigational triple ... (40/10/25 mg) resulted in a statistically significant greater Least ... at week 12 (37.9/22.0 mm Hg versus 26.4-28.0/14.7-17.6 mm ...
... , June 28 Codexis, Inc. (Nasdaq: CDXS ... company as Senior Vice President, Commercial Operations, a new position.  Mr. ... operations worldwide.  He will report to Joseph Sarret , M.D., ... , , , ...
Cached Medicine Technology:New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 2New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 3New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 4New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 5New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 6New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 7Codexis Names Peter Strumph SVP, Commercial Operations 2
(Date:5/23/2013)... 2013 Canadian Healthy Vending ... Vending Machines, and that's in sync with the preference ... the Canada Organic Trade Association (COTA). The report says ... beverages each year. This makes the burgeoning organic market ... , As a Canadian leader in healthy vending machines, ...
(Date:5/23/2013)... OnSomble, Inc. has partnered with The Aroostook Medical ... and empower nurses to work at their full capacity. ... services and chief nursing officer at The Aroostook Medical ... want to help them take the next step in ... follow, encourage them to take pride in being a ...
(Date:5/23/2013)... Great defined abs are the embodiment of being ... achieve in the gym yet so many fall short of ... goal become a reality. Great abdominal muscles are acquired in ... Scott Tischler of Tischler Brothers Fitness explains four of these ... of great abs. , 1.    Go to bed early. The body ...
(Date:5/23/2013)... Better Life Maids of Portland Oregon is putting on the ... of a kind green house cleaning service in the Portland ... 29th, and a soft opening scheduled for June 3rd, 2013. ... Portland recently and will travel to St. Louis June 26th ... is a lot to take in" stated Heather Richardson. "Better ...
(Date:5/23/2013)... Pittsburgh-based company Automated Security Alert focuses ... own homes for as long as possible. Jason ... commented on how the company differs from other medical ... are numerous companies in the United States that offer ... they are dedicated only to health and well-being while ...
Breaking Medicine News(10 mins):Health News:Max! Healthy Vending Machines in Tune with Burgeoning Organic Foods Market 2Health News:OnSomble, Inc. Partners with The Aroostook Medical Center to Enhance Nurse Understanding of the Professional Role 2Health News:Scott Tischler of Tischler Brothers Fitness Unveils the 4 Secrets to Getting Abs this Summer 2Health News:Better Life Maids of Portland Oregon Prepares For a Summer of 2013 Launch 2Health News:Automated Security Alert's New Medical Alarm Works Even In Power Outages 2
... ... titanium ring studios shows that single women shop for engagement rings before meeting the partner they ... ... design studios, TiRings.com, has revealed evidence that shows a tendency among single women to shop for ...
... ... is the leading supplier of software & technology to Home Medical ... Health Care Agencies. Only Fastrack offers a solution for each ... virtually every clinical, operational and financial aspect of a provider’s business, ...
... The ... and other metal products. In addition to revealing the personality and culture of The Monterey ... pins, and an informal forum for discussions related to such products. , ... (PRWEB) May 8, 2010 -- This year has been a ...
... carbonated soft drinks is not associated with the risk of ... 7 in the Journal of the National Cancer Institute. ... and tea may lower the risk of cancer, but others ... contains anti-oxidants that in theory help prevent cancer but also ...
... ... Beauty, Fighting the Aging Process and Maintaining a Youthful, “Close-Up-Ready” Appearance , ... Los Angeles, CA (PRWEB) May ... have begun to open up about using non-surgical aesthetic procedures to maintain their youthful, ...
... ... religion’s first book this weekend. Published May 9, 1950, “Dianetics: The Modern Science of ... , ... 2010 -- Churches of Scientology around the world celebrate the original release of ...
Cached Medicine News:Health News:Statistics Reveal Women Choose Engagement Rings Before Men 2Health News:Fastrack Acquires Prometheus Group Industry Leading HME Billing Service 2Health News:Monterey Lapel Pin Company Continues Its Website Evolution 2Health News:Monterey Lapel Pin Company Continues Its Website Evolution 3Health News:Coffee and soft drinks have little or no association with colon cancer risk 2Health News:Achieve Hollywood Glamour with Non-Surgical Cosmetic Procedures 2Health News:Achieve Hollywood Glamour with Non-Surgical Cosmetic Procedures 3Health News:Scientology Churches Celebrate Dianetics 60th Anniversary 2
... 1-step, hand-held, point-of-care device for the qualitative detection ... The TOX/See device can detect up to ... 3 to 8 minutes and requires only a ... individually packaged to maximize convenience and ease of ...
... point-of-care device for the qualitative detection of drug ... TOX/See device can detect up to nine of ... 8 minutes and requires only a few drops ... to maximize convenience and ease of use. TOX/See ...
... hand-held, point-of-care device for the qualitative detection of ... The TOX/See device can detect up to nine ... to 8 minutes and requires only a few ... packaged to maximize convenience and ease of use. ...
... TOX/See™ is a 1-step, hand-held, point-of-care device ... metabolites in human urine. The TOX/See device ... commonly abused drugs in 3 to 8 minutes ... Each TOX/See cassette is individually packaged to maximize ...
Medicine Products: